GEN News Highlights

Regeneron, Bayer Confirm Australian Approval of Eylea for Wet AMD

(Page
1
of
1)

Regeneron Pharmaceuticals and Bayer HealthCare confirmed Australian regulatory approval for Eylea® (aflibercept) injection, for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). FDA approved the drug for the same indication in November 2011. Austalian clearance of Eylea was based on data from the Phase II View 1 and View 2 trials, which demonstrated that the drug was no less effective than more frequent injections of Lucentis (ranibizumab) in terms of maintaining visual acuity.

Eylea is currently undergoing Phase III development for wet AMD in China, and regulatory filings have been made in Euope, Japan, and other countries. The drug is in addition being evaluated in Phase III studies as a treatment for diabetic macular edema, myopic choroidal neovascularisation, and branch retinal vein occlusion. An sBLA for the use of Eylea in the treatment of central vein retinal occlusion has been filed in the U.S.

Eylea (also known as VEGF Trap-Eye) is a recombinant fusion protein comprising parts of the human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1. The drug is formulated for administration as an intravitreal injection. Bayer HealthCare and Regeneron are collaborating on global development, with Regeneron retaining exclusive rights to Eylea in the U.S., and Bayer Healthcare retaining exclusive marketing rights outside the U.S., where the partners will share equally on profits from future sales.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

57.3%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.